Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

This study aims to evaluate the non-inferiority in recurrence-free survival and overall survival of segmentectomy compared with lobectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype negative by intraoperative frozen sections.

Trial Details

NCT ID
NCT04937283
Phase
NA
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Segmentectomy
  • Lobectomy
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Nanyang, Henan, China|33.00524,112.54659
  • Nantong, Jiangsu, China|32.03028,120.87472
  • Nantong, Jiangsu, China|32.03028,120.87472

Key Eligibility Criteria

  • Patient aged 20-79 years old, both male or female;
  • Tumor size \<= 2cm on preoperative CT scan;
  • Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion;
  • Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio \>= 0.25);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →